Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in:

31-08-2023 | Parkinson Disease | Review Article

The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson’s Disease

Authors: Udit Saraf, Amit Batla, Ryuji Sakakibara, Jalesh N. Panicker

Published in: Drugs & Aging | Issue 10/2023

Login to get access

Abstract

Lower urinary tract (LUT) symptoms are a common presentation of autonomic dysfunction in Parkinson’s disease (PD). Symptoms significantly impact quality of life and are associated with worsening of motor symptoms and increased risk for falls. Different medical co-morbidities can often contribute to LUT symptoms, and a thorough evaluation therefore becomes essential. The effects of medications used for Parkinson’s disease and other co-existing medical co-morbidities on LUT symptoms is often underestimated. Treatment options include behavioural therapy, oral agents such as antimuscarinic and beta-3 receptor agonist agents, botulinum toxin and neuromodulation. The first-line oral agents cause adverse effects that may exacerbate pre-existing Parkinson’s disease-related symptoms. Furthermore, these oral agents can interact with other medications used in Parkinson’s disease, and the challenges posed by interactions on pharmacological effects and metabolism are discussed. Knowledge about drug interactions can help in effective management of such patients and mitigate the risks for developing adverse effects.
Literature
1.
Ragab MM, Mohammed ES. Idiopathic Parkinson’s disease patients at the urologic clinic. Neurourol Urodyn. 2011;30(7):1258–61.PubMedCrossRef
2.
Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci. 2001;92(1–2):76–85.PubMedCrossRef
3.
Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25(15):2493–500.PubMedCrossRef
4.
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9.PubMedCrossRef
5.
Andersen JT. Disturbances of bladder and urethral function in Parkinson’s disease. Int Urol Nephrol. 1985;17(1):35–41.PubMedCrossRef
6.
Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson’s disease. J Urol. 1987;138(4):836–8.PubMedCrossRef
7.
Rosello A, Pouwels KB, Domenech DECM, Vank E, Hayward AC, Hopkins S, et al. Seasonality of urinary tract infections in the United Kingdom in different age groups: longitudinal analysis of The Health Improvement Network (THIN). Epidemiol Infect. 2018;146(1):37–45.PubMedCrossRef
8.
Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol. 2005;252(11):1310–5.PubMedCrossRef
9.
Temml C, Ponholzer A, Gutjahr G, Berger I, Marszalek M, Madersbacher S. Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn. 2009;28(8):949–52.PubMedCrossRef
10.
McGrother CW, Jagger C, Clarke M, Castleden CM. Handicaps associated with incontinence: implications for management. J Epidemiol Community Health. 1990;44(3):246–8.PubMedPubMedCentralCrossRef
11.
Yeo L, Singh R, Gundeti M, Barua JM, Masood J. Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol. 2012;44(2):415–24.PubMedCrossRef
12.
Xu D, Han S, Wang J, Feng J. Relationship between lower urinary tract dysfunction and clinical features in Chinese Parkinson’s disease patients. Parkinsons Dis. 2019;2019:6820937.PubMedPubMedCentral
13.
Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12(11):842–50.PubMedCrossRef
14.
Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46(3):565–71.PubMedCrossRef
15.
Batla A, Tayim N, Pakzad M, Panicker JN. Treatment options for urogenital dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2016;18(10):45.PubMedPubMedCentralCrossRef
16.
Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, Yoshimura N. Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol. 2017;14(2):79–89.PubMedCrossRef
17.
Yamamoto T, Asahina M, Yamanaka Y, Uchiyama T, Hirano S, Fuse M, et al. The utility of post-void residual volume versus sphincter electromyography to distinguish between multiple system atrophy and Parkinson’s disease. PLoS ONE. 2017;12(1): e0169405.PubMedPubMedCentralCrossRef
18.
Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, et al. Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord. 2015;30(3):411–5.PubMedCrossRef
19.
Ransmayr GN, Holliger S, Schletterer K, Heidler H, Deibl M, Poewe W, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70(4):299–303.PubMedCrossRef
20.
Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc. 1992;40(12):1217–20.PubMedCrossRef
21.
Nakagawa H, Niu K, Hozawa A, Ikeda Y, Kaiho Y, Ohmori-Matsuda K, et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. 2010;184(4):1413–8.PubMedCrossRef
22.
Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104(1):63–8.PubMedPubMedCentralCrossRef
23.
24.
Batla A, Simeoni S, Uchiyama T, deMin L, Baldwin J, Melbourne C, et al. Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson’s disease. Eur J Neurol. 2021;28(6):1884–92.PubMedCrossRef
25.
Batla A, Phe V, De Min L, Panicker JN. Nocturia in Parkinson’s disease: why does it occur and how to manage? Mov Disord Clin Pract. 2016;3(5):443–51.PubMedPubMedCentralCrossRef
26.
Sakakibara R, Shimizu A, Takahashi O, Ogata T, Sawai S, Uchiyama T, et al. Parkinson’s disease and nocturnal polyuria. Neurol Clin Neurosci. 2023;11(1):27–31.CrossRef
27.
Li FF, Cui YS, Yan R, Cao SS, Feng T. Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14: 977572.PubMedPubMedCentralCrossRef
28.
Sammour ZM, Gomes CM, Barbosa ER, Lopes RI, Sallem FS, Trigo-Rocha FE, et al. Voiding dysfunction in patients with Parkinson’s disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn. 2009;28(6):510–5.PubMedCrossRef
29.
Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease—should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.PubMedCrossRef
30.
Iacovelli E, Gilio F, Meco G, Fattapposta F, Vanacore N, Brusa L, et al. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson’s disease. Mov Disord. 2010;25(9):1203–9.PubMedCrossRef
31.
Godmer M, Guinet-Lacoste A, Charvier K, Luauté J, Rode G, Soler JM, et al. Existe-t-il une obstruction autre que prostatique dans la maladie de Parkinson idiopathique? Prog Urol. 2019;29(11):579–85.PubMedCrossRef
32.
McDonald C, Rees J, Winge K, Newton JL, Burn DJ. Bladder training for urinary tract symptoms in Parkinson disease: a randomized controlled trial. Neurology. 2020;94(13):e1427–33.PubMedPubMedCentralCrossRef
33.
Vaughan CP, Burgio KL, Goode PS, Juncos JL, McGwin G, Muirhead L, et al. Behavioral therapy for urinary symptoms in Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2019;38(6):1737–44.PubMedPubMedCentralCrossRef
34.
Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee TNPCiTICS. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.PubMedCrossRef
35.
Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68(18):1455–9.PubMedCrossRef
36.
Brusa L, Ponzo V, Stefani A, Ceravolo R, Palermo G, Agro EF, et al. Extended release levodopa at bedtime as a treatment for nocturiain Parkinson’s disease: an open label study. J Neurol Sci. 2020;410: 116625.PubMedCrossRef
37.
Gomez-Lopez A, Sanchez-Sanchez A, Natera-Villalba E, Ros-Castello V, Beltran-Corbellini A, Fanjul-Arbos S, et al. SURINPARK: safinamide for urinary symptoms in Parkinson's Disease. Brain Sci. 2021;11(1):57.
38.
Tateno H, Uchiyama T, Yamamoto T, Watanabe Y, Hashimoto K, Shibata-Yamaguchi C, et al. Amantadine can ameliorate lower urinary tract dysfunction and nocturnal polyuria in patients with Parkinson disease and vascular parkinsonism. Dokkyo J Med Sci. 2015;42(1):21–9.
39.
Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):514–20.PubMedCrossRef
40.
Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, Sigala S, et al. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Clin Neuropharmacol. 2006;29(4):220–9.PubMedCrossRef
41.
Bennett N, O’Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004;171(2 Pt 1):749–51.PubMedCrossRef
42.
Macdiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol. 2008;10(2):92–8.PubMedPubMedCentral
43.
Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8(8):1181–8.PubMedPubMedCentralCrossRef
44.
Bharucha AE, Isowa H, Hiro S, Guan Z. Differential effects of selective and non-selective muscarinic antagonists on gastrointestinal transit and bowel function in healthy women. Neurogastroenterol Motil. 2013;25(1):e35–43.PubMedCrossRef
45.
Provitera V, Nolano M, Caporaso G, Stancanelli A, Mozzillo S, Piscosquito G, et al. Asymmetric sudomotor impairment in Parkinson disease. Clin Neurophysiol. 2019;130(1): e11.CrossRef
46.
Ahmad S, Reyes JVM, Lieber J. Oxybutynin-induced hyperthermia in a patient with Parkinson’s disease. Cureus. 2021;13(4): e14701.PubMedPubMedCentral
47.
Madan A, Brown T, Ray S, Agarwal P, Roy-Faderman I, Burdick D. A novel trial of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in Parkinson’s disease (MAESTRO). Cureus. 2022;14(11): e31818.PubMedPubMedCentral
48.
Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged >/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–20.PubMedCrossRef
49.
Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord. 1995;10(3):337–40.PubMedCrossRef
50.
Fralick M, Schneeweiss S, Wallis CJD, Jung EH, Kesselheim AS. Desmopressin and the risk of hyponatremia: a population-based cohort study. PLoS Med. 2019;16(10): e1002930.PubMedPubMedCentralCrossRef
51.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.PubMedPubMedCentralCrossRef
52.
Hu J-C, Hsu L-N, Lee W-C, Chuang Y-C, Wang H-J. Role of urological botulinum toxin-a injection for overactive bladder and voiding dysfunction in patients with Parkinson’s disease or post-stroke. Toxins (Basel). 2023;15(2):166.PubMedPubMedCentralCrossRef
53.
Atamian A, Sichez PC, Michel F, Bandelier Q, Fall M, Gaillet S, et al. Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson’s disease. Prog Urol. 2021;31(7):430–8.PubMedCrossRef
54.
Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960–4.PubMedCrossRef
55.
Knüpfer SC, Schneider SA, Averhoff MM, Naumann CM, Deuschl G, Jünemann K-P, et al. Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease. BMC Urol. 2016;16(1):55.PubMedPubMedCentralCrossRef
56.
Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson’s disease. Urology. 2014;83(1):22–7.PubMedCrossRef
57.
Vurture G, Peyronnet B, Feigin A, Biagioni MC, Gilbert R, Rosenblum N, et al. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson’s disease. Neurourol Urodyn. 2018;37(8):2669–77.PubMedCrossRef
58.
Kabay S, Kabay SC. The sustained therapeutic effects of percutaneous posterior tibial nerve stimulation in the treatment of neurogenic lower urinary tract symptoms in patients with Parkinson’s disease: 24-months clinical and urodynamic results. Urology. 2021;153:49–55.PubMedCrossRef
59.
Araujo TG, Schmidt AP, Sanches PRS, Silva Junior DP, Rieder CRM, Ramos JGL. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2021;40(1):538–48.PubMedCrossRef
60.
Perissinotto MC, D’Ancona CA, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Cont Nurs. 2015;42(1):94–9.CrossRef
61.
McClurg D, Elders A, Hagen S, Mason H, Booth J, Cunnington AL, et al. Stimulation of the tibial nerve—a randomised trial for urinary problems associated with Parkinson's—the STARTUP trial. Age Ageing. 2022;51(6):afac114.
62.
Martin S, Zillioux J, Goldman HB. Is sacral neuromodulation effective in patients with Parkinson’s disease? A retrospective review. Neurourol Urodyn. 2022;41(4):955–61.PubMedCrossRef
63.
Macleod AD, Goddard H, Counsell CE. Co-morbidity burden in Parkinson’s disease: comparison with controls and its influence on prognosis. Parkinsonism Relat Disord. 2016;28:124–9.PubMedPubMedCentralCrossRef
64.
McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126.PubMedPubMedCentralCrossRef
65.
Minar M, Dragasek J, Valkovic P, Valkovic P. Psychiatric and somatic co-morbidities in patients with Parkinson’s disease: a STROBE-compliant national multi-center, cross-sectional, observational study COSMOS in Slovakia. Neuro Endocrinol Lett. 2022;43(1):39–44.PubMed
66.
Bhagavathula AS, Tesfaye W, Vidyasagar K, Fialova D. Polypharmacy and Hyperpolypharmacy in older individuals with Parkinson's disease: a systematic review and meta-analysis. Gerontology. 2022;68(10):1081–90.
67.
Srikrishna S, Robinson D, Cardozo L. Important drug–drug interactions for treatments that target overactive bladder syndrome. Int Urogynecol J. 2014;25(6):715–20.PubMedCrossRef
68.
Vouri SM, Schootman M, Strope SA, Xian H, Olsen MA. Antimuscarinic use and discontinuation in an older adult population. Arch Gerontol Geriatr. 2019;80:1–11.PubMedCrossRef
69.
Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol. 2012;8(11):1387–408.PubMedCrossRef
70.
Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, et al. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014;39(1):43–52.PubMedCrossRef
71.
De Vreese LP, Mantesso U, De Bastiani E, Marangoni A, Weger E, Gomiero T. Anticholinergic burden in adult and elderly people with intellectual disabilities: results from an Italian multicenter cross-sectional study. PLoS ONE. 2018;13(10): e0205897.PubMedPubMedCentralCrossRef
72.
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.CrossRef
73.
Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. 2018;35(6):523–38.PubMedCrossRef
74.
De Germay S, Montastruc J-L, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, et al. Atropinic (anticholinergic) burden in Parkinson’s disease. Mov Disord. 2016;31(5):632–6.PubMedCrossRef
75.
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.PubMedPubMedCentralCrossRef
76.
Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183–90.PubMedCrossRef
77.
Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–201.PubMedCrossRef
78.
Dewey SL, Volkow ND, Logan J, MacGregor RR, Fowler JS, Schlyer DJ, et al. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J Neurosci Res. 1990;27(4):569–75.PubMedCrossRef
79.
Rajan R, Saini A, Verma B, Choudhary N, Gupta A, Vishnu VY, et al. Anticholinergics may carry significant cognitive and gait burden in Parkinson’s disease. Mov Disord Clin Pract. 2020;7(7):803–9.PubMedPubMedCentralCrossRef
80.
Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021;18(11):686–700.PubMedCrossRef
81.
Taylor-Rowan M, Edwards S, Noel-Storr AH, McCleery J, Myint PK, Soiza R, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5(5):CD013540.PubMed
82.
Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808–13.PubMedCrossRef
83.
Averbeck MA, Altaweel W, Manu-Marin A, Madersbacher H. Management of LUTS in patients with dementia and associated disorders. Neurourol Urodyn. 2017;36(2):245–52.PubMedCrossRef
84.
Kröger E, Van Marum R, Souverein P, Carmichael PH, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015;24(3):276–85.PubMedCrossRef
85.
Ishii N, Mochizuki H, Sakai K, Ogawa G, Shiomi K, Nakazato M. Polypharmacy associated with cognitive decline in newly diagnosed Parkinson’s disease: a cross-sectional study. Dement Geriatr Cogn Dis Extra. 2019;9(3):338–43.PubMedPubMedCentralCrossRef
86.
Sumbul-Sekerci B, Bilgic B, Pasin O, Emre M, Hanagasi HA. Anticholinergic burden, polypharmacy, and cognition in Parkinson's disease patients with mild cognitive impairment: a cross-sectional observational study. Dement Geriatr Cogn Disord. 2022;51(5):386–95.
87.
Bohnen NI, Yarnall AJ, Weil RS, Moro E, Moehle MS, Borghammer P, et al. Cholinergic system changes in Parkinson’s disease: emerging therapeutic approaches. Lancet Neurol. 2022;21(4):381–92.PubMedPubMedCentralCrossRef
88.
Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74(1):70–6.PubMedPubMedCentralCrossRef
89.
Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit. 2000;6(2):314–8.PubMed
90.
Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235–46.PubMedPubMedCentralCrossRef
91.
Geller EJ, Dumond JB, Bowling JM, Khandelwal CM, Wu JM, Busby-Whitehead J, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118–23.PubMedCrossRef
92.
Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25–35.PubMedCrossRef
93.
Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–26.PubMedCrossRef
94.
Bozkurt IH, Sefik E, Celik S, Yesilova A, Koras O, Degirmenci T. On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics. Int Urogynecol J. 2022;33(8):2127–32.PubMedCrossRef
Metadata
Title
The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson’s Disease
Authors
Udit Saraf
Amit Batla
Ryuji Sakakibara
Jalesh N. Panicker
Publication date
31-08-2023
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 10/2023
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-023-01060-2

Other articles of this Issue 10/2023

Drugs & Aging 10/2023 Go to the issue

Review Article

Crushed Tablet Administration for Patients with Dysphagia and Enteral Feeding: Challenges and Considerations

Current Opinion

Evaluation and Treatment of Acute Trauma Pain in Older Adults

Original Research Article

Secular Trends in Central Nervous System-Active Polypharmacy Among Serial Cross-Sections of US Adults, 2009–2020

Original Research Article

Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study

Original Research Article

Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study

Systematic Review

Hypertension Treatment in Frail Older Adults: A Systematic Review and Appraisal of Guidelines

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits